



Standard Treatment Workflow (STW) for the Management of **ADULT PERICARDIAL TUBERCULOSIS**

ICD-10-A18.84

WHEN TO SUSPECT

SYMPTOMS

- · Cough, fever, breathlessness or pleuritic chest pain
- May be associated with weight loss, night sweats or difficulty lying down
- Past history or a history of contact with a patient with a diagnosis of tuberculosis
- Examination reveals tachycardia, increased jugular venous pressure, hepatomegaly, ascites, & peripheral edema
- · A pericardial friction rub and distant heart sounds present on cardiovascular examination
- If clinical picture +/- heart US suggest pericarditis or pericardial effusion refer for echo-cardiogram

COMPLICATIONS

Constrictive pericarditis: Clinical signs for recognition include

- · Kussmaul's sign (lack of an inspiratory decline in jugular venous pressure)
- Elevated & distended jugular veins with a prominent Y descent (second inward deflection of internal jugular pulse due to diastolic inflow of blood into the right ventricle)
- Pericardial knock (rare)

- Cardiac tamponade: Clinical signs include
- Sinus tachycardia
- Hypotension with a narrow pulse pressure
- Elevated JVP jugular venous pressure
- Muffled heart sounds
- Pulsus paradoxus (a decrease in systolic blood pressure by >10 mmHg on inspiration)
- Ascites

Essential tests:

- Chest X-ray
- ECG
- Echocardiogram

INVESTIGATION


Desirable:

- Cardiac enzymes
- CT/MRI of Thorax
- Pericardiocentesis Pericardial biopsy

Other complications:

- · Myopericarditis: Abnormal ejection fraction with evidence of myocarditis and pericarditis (elevated cardiac enzymes & ST elevation on ECG)
- Effusive constrictive pericarditis: Mixed clinical picture. Main clue is elevated JVP clinically & right atrial pressure on ECHO in spite of removal of pericardial fluid

DIAGNOSIS



MANAGEMENT

Start ATT

TREATMENT

trial of ATT

- Antitubercular therapy is advised as per NTEP
- Steroids are recommended in large pericardial effusions, prominent pleocytosis & pericardial fluid with high inflammatory markers or early constriction
- Give Prednisolone 60 mg/day for 4 weeks, 30 mg/day for 4 weeks, 15 mg/day for 2 weeks & 5 mg/day for 1 week
- Total duration of systemic steroids is 11 weeks

NON RESPONSE TO STEROIDS & ATT

Continue ATT and check response

- · Should prompt a referral to a specialist center for confirmation of diagnosis
- Should prompt an evaluation for alternative causes of effusio-constrictive pericarditis: viral infections, systemic lupus erythematosus, primary effusion lymphomas or pericardial malignancies
- Non response of cardiac symptoms to anti-tuberculous therapy cardiac surgical evaluation may be required

ABBREVIATION

ADA: Adenosine Deaminase ATT: Antituberculous Therapy

treatment

CXR: Chest X-ray ECG: Electrocardiogram **ECHO: Echocardiogram**

JVP: Jugular Venous Pressure NTEP: National Tuberculosis Elimination Programme **TB: Tuberculosis**

- 1. National TB Elimination Programme, Central TB Division. Training Modules for Programme Managers & Medical Officers. Ministry of Health & Family Welfare, Government of India accessed at
- https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=5465&lid=3540 Last access on 15 March, 2022. 2. Guidelines for programmatic management of drug resistant tuberculosis in India March 2021. National TB Elimination Programme, Central TB Division, Ministry of Health & Family Welfare,
- Government of India https://tbcindia.gov.in/showfile.php?lid=3590 Last access on 15 March, 2022. 3. Nahid P. Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the

treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit our web portal (stw.icmr.org.in) for more information. © Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Government of India.

of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.